Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 30.7% in January

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 31st total of 457,100 shares. Currently, 22.4% of the company’s stock are sold short. Based on an average daily trading volume, of 421,900 shares, the short-interest ratio is presently 1.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Price Performance

Shares of ALGS stock opened at $23.74 on Friday. The company has a market cap of $85.18 million, a P/E ratio of -1.78 and a beta of 2.50. The stock’s 50-day moving average is $32.59 and its 200 day moving average is $19.07. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The firm had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same quarter in the prior year, the business posted ($10.25) earnings per share. On average, analysts anticipate that Aligos Therapeutics will post -10.36 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. AlphaMark Advisors LLC boosted its position in shares of Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after purchasing an additional 1,000 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in Aligos Therapeutics in the fourth quarter worth about $107,000. Finally, Drive Wealth Management LLC purchased a new stake in shares of Aligos Therapeutics during the fourth quarter worth about $916,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).